查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1974469

蛋白质治疗市场分析及预测（至2035年）：类型、产品类型、技术、应用、最终用户、剂型、製程、安装类型、设备

Protein Therapeutics Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Form, Process, Installation Type, Equipment
出版日期: | 出版商: Global Insight Services | 英文 494 Pages | 商品交期: 3-5个工作天内

价格
简介目录

蛋白质疗法市场预计将从2024年的3,760亿美元成长到2034年的7,408亿美元，复合年增长率约为7%。蛋白质疗法市场涵盖用于治疗多种疾病的生物来源蛋白质疗法。该市场包括单株抗体、疫苗和肽激素，这些疗法可提供高度特异性的标靶治疗。慢性病发病率的上升和生物技术的进步正在推动市场成长，蛋白质工程和递送系统的创新提高了治疗效果和患者预后。监管支持和医疗保健支出的成长也进一步推动了市场扩张。

全球关税和地缘政治紧张局势正严重影响蛋白质疗法市场，尤其是在东亚地区。日本和韩国正加大对生物製药创新领域的策略性投资，以降低进口依赖并应对关税的影响。中国在出口限制下，正着力提升生物製药能力，以实现自给自足；而台湾则凭藉其先进的製造能力，力求在地缘政治脆弱性面前保持关键地位。在生物製药和个人化医疗技术的推动下，全球蛋白质疗法市场保持强劲成长。预计到2035年，在区域合作和生物相似药创新的推动下，市场将持续成长。中东衝突透过加剧能源价格波动并可能扰乱生产和物流，间接影响该市场，凸显了建立具有韧性的供应链策略的必要性。

市场区隔
类型 单株抗体、胰岛素、红血球生成素、干扰素、集落刺激因子、生长激素、凝血因子、酵素替代疗法
产品 治疗性蛋白质、疫苗、肽激素、血液因子
科技 重组DNA技术、融合瘤技术、基因改造技术、细胞培养
应用 癌症、代谢性疾病、血液疾病、自体免疫疾病、感染疾病、神经系统疾病
最终用户 医院、诊所、研究机构、生物製药公司
剂型 注射、口服剂、吸入剂、外用剂
流程 纯化、配製和冻干
安装表格 内部、外包
装置 生物反应器、层析法系统、过滤系统

由于生物技术的进步和慢性病发病率的上升，蛋白质疗法市场正经历强劲成长。单株抗体领域表现良好，这得益于其在治疗多种疾病方面的特异性和疗效。在该领域中，癌症和自体免疫疾病这两个子领域表现尤为突出，反映了它们巨大的治疗潜力。治疗性蛋白质领域也呈现成长态势，其中酵素和荷尔蒙在治疗代谢和荷尔蒙失调方面发挥关键作用。

融合蛋白也日益受到关注，尤其是在肿瘤和感染疾病领域，它们能够提高疗效并减少副作用。受成本效益和多种生物製药专利到期，生物相似药的需求不断增长，为市场参与者提供了盈利的机会。药物递送系统和个人化医疗的创新进一步推动了市场发展。在这个瞬息万变的环境中，策略合作和研发投入对于抓住新机会、保持竞争优势至关重要。

蛋白质疗法市场呈现出市场份额多元化的特点，其价格环境受技术进步和策略联盟的影响而呈现动态变化。近期新产品的推出为市场注入了活力，体现了企业对创新和满足未被满足的医疗需求的重视。主要企业正积极拓展产品系列，提升疗效，并进军细分市场。市场正经历着向个人化医疗的转变，这推动了对新型蛋白质疗法的需求。北美继续保持主导地位，而新兴经济体则提供了盈利的成长机会。

竞争基准分析显示，市场竞争激烈，策略联盟并存。各公司正利用最尖端科技取得竞争优势。监管影响至关重要，北美和欧洲严格的监管准则塑造市场动态。法规环境既促进了创新，也保障了病人安全。新兴市场正在适应全球标准，这既带来了挑战，也带来了机会。在科技进步和医疗保健投资不断增长的推动下，市场正处于成长轨道上。儘管高昂的研发成本和复杂的监管流程等挑战依然存在，但突破性治疗方法的潜力依然巨大。

主要趋势和驱动因素：

受生物技术进步和慢性病盛行率快速上升的推动，蛋白质疗法市场正经历强劲成长。生物製药领域的创新正在推动新型蛋白质疗法的研发，这些疗法能够提高治疗效果并改善患者预后。与传统药物相比，这些疗法具有更高的特异性和更少的副作用，因此正日益受到认可。

关键趋势包括单株抗体的应用日益广泛，其在癌症和自体免疫疾病的标靶治疗中正获得越来越多的定向。此外，由于专利到期以及对经济高效替代疗法的需求，生物相似药的需求也在不断增长。法规结构的完善进一步推动了这一趋势，这些框架简化了生物相似药的核准，并加快了其市场准入。

此外，个人化医疗正成为关键驱动力，其中蛋白质疗法在开发针对个人基因谱的客製化治疗方法方面发挥着至关重要的作用。研发投入推动创新，而生技公司与学术机构的合作则加速了发现进程。对精准医疗和标靶治疗的日益关注，为蛋白质疗法领域创造了盈利的机会，预计未来几年将迎来显着的市场扩张。

限制与挑战：

蛋白质疗法市场面临许多重大限制和挑战。其中一个突出的挑战是高昂的研发和生产成本，加重了生产者和消费者的经济负担。监管障碍进一步阻碍了市场准入，严格的合规要求需要花费大量时间和资源。智慧财产权问题也构成障碍，专利到期加剧了生物相似药的竞争。此外，蛋白质疗法的复杂性需要复杂的储存和分销基础设施，这带来了物流方面的挑战并增加了成本。最后，由于价格高昂和报销问题，患者获取药物的机会有限，这阻碍了市场扩张，尤其是在发展中地区。这些因素共同限制了蛋白质疗法市场的成长和广泛应用。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 胰岛素
    • 促红血球生成素
    • 干扰素
    • 集落刺激因子
    • 生长激素
    • 凝血因子
    • 酵素替代疗法
  • 市场规模及预测：依产品划分
    • 治疗性蛋白质
    • 疫苗
    • 肽激素
    • 血液因子
  • 市场规模及预测：依技术划分
    • 重组DNA技术
    • 融合瘤技术
    • 基因改造技术
    • 细胞培养
  • 市场规模及预测：依应用领域划分
    • 癌症
    • 代谢性疾病
    • 血液疾病
    • 自体免疫疾病
    • 感染疾病
    • 神经系统疾病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 医疗
    • 研究所
    • 生物製药公司
  • 市场规模及预测：依类型
    • 注射
    • 口服
    • 吸入剂
    • 主题
  • 市场规模及预测：依製程划分
    • 纯化
    • 配方
    • 冷冻干燥
  • 市场规模及预测：依安装类型划分
    • 内部开发
    • 外包
  • 市场规模及预测：依设备划分
    • 生物反应器
    • 层析法系统
    • 过滤系统

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Biocon
  • Sangamo Therapeutics
  • AbCellera Biologics
  • MacroGenics
  • Adaptimmune Therapeutics
  • BioNTech
  • CureVac
  • ImmunoGen
  • Kymab
  • Morphic Therapeutic
  • Pieris Pharmaceuticals
  • Sorrento Therapeutics
  • Argenx
  • Aptevo Therapeutics
  • Alector
  • Zymeworks
  • Allakos
  • Gritstone Oncology
  • Gossamer Bio
  • Harpoon Therapeutics

第九章：关于我们

简介目录
Product Code: GIS33198

Protein Therapeutics Market is anticipated to expand from $376.0 Billion in 2024 to $740.8 Billion by 2034, growing at a CAGR of approximately 7%. The Protein Therapeutics Market encompasses biologically-derived treatments using proteins to address various medical conditions. This market includes monoclonal antibodies, vaccines, and peptide hormones, offering targeted therapies with high specificity. The increasing prevalence of chronic diseases and advancements in biotechnology fuel market growth, with innovations in protein engineering and delivery systems enhancing therapeutic efficacy and patient outcomes. Regulatory support and rising healthcare expenditures further bolster market expansion.

Global tariffs and geopolitical tensions are profoundly influencing the Protein Therapeutics Market, particularly in East Asia. Japan and South Korea are strategically investing in biopharmaceutical innovation to mitigate reliance on imports and counter tariff impacts. China is accelerating its biopharma capabilities, focusing on self-sufficiency amidst export restrictions, while Taiwan leverages its advanced manufacturing to remain a pivotal player despite geopolitical vulnerabilities. The global protein therapeutics market is robust, driven by advancements in biologics and personalized medicine. By 2035, growth is anticipated to be sustained through regional collaborations and innovation in biosimilars. Middle East conflicts indirectly affect this market by exacerbating energy price volatility, which could disrupt manufacturing and logistics, highlighting the need for resilient supply chain strategies.

Market Segmentation
TypeMonoclonal Antibodies, Insulin, Erythropoietin, Interferons, Colony Stimulating Factors, Growth Hormones, Coagulation Factors, Enzyme Replacement
ProductTherapeutic Proteins, Vaccines, Peptide Hormones, Blood Factors
TechnologyRecombinant DNA Technology, Hybridoma Technology, Transgenic Technology, Cell Culture
ApplicationCancer, Metabolic Disorders, Blood Disorders, Autoimmune Diseases, Infectious Diseases, Neurological Disorders
End UserHospitals, Clinics, Research Institutes, Biopharmaceutical Companies
FormInjectable, Oral, Inhalable, Topical
ProcessPurification, Formulation, Lyophilization
Installation TypeIn-House, Outsourced
EquipmentBioreactors, Chromatography Systems, Filtration Systems

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and increasing prevalence of chronic diseases. The monoclonal antibodies segment leads in performance, due to their specificity and effectiveness in treating various conditions. Within this segment, cancer and autoimmune diseases are top-performing sub-segments, reflecting their significant therapeutic potential. The therapeutic proteins segment follows closely, with enzymes and hormones being pivotal in addressing metabolic and hormonal disorders.

Fusion proteins are also gaining traction, particularly in oncology and infectious diseases, offering enhanced efficacy and reduced side effects. The demand for biosimilars is rising, driven by cost-effectiveness and the expiration of patents for several biologics, providing lucrative opportunities for market players. Innovations in drug delivery systems and personalized medicine are further propelling the market. Strategic collaborations and investments in R&D are crucial for capturing emerging opportunities and sustaining competitive advantage in this dynamic landscape.

The Protein Therapeutics Market is characterized by diverse market share, with a dynamic pricing landscape influenced by technological advancements and strategic alliances. Recent product launches have invigorated the market, reflecting innovation and a focus on addressing unmet medical needs. Key players are actively engaged in expanding their portfolios, enhancing therapeutic efficacy, and targeting niche segments. The market is witnessing a shift towards personalized medicine, driving demand for novel protein-based therapies. North America remains a dominant force, while emerging economies present lucrative opportunities for growth.

Competition benchmarking reveals a landscape marked by intense rivalry and strategic collaborations. Companies are leveraging cutting-edge technologies to gain competitive advantages. Regulatory influences play a pivotal role, with stringent guidelines in North America and Europe shaping market dynamics. The regulatory environment fosters innovation while ensuring patient safety. Emerging markets are adapting to global standards, presenting both challenges and opportunities. The market's trajectory is poised for growth, driven by scientific advancements and increasing healthcare investments. Challenges such as high development costs and complex regulatory pathways persist, yet the potential for groundbreaking therapies remains substantial.

Geographical Overview:

The protein therapeutics market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains at the forefront, driven by advanced healthcare infrastructure and significant R&D investments. The presence of key industry players further bolsters the region's market dominance. Europe follows closely, with strong government support and a focus on biopharmaceutical innovation enhancing market prospects. The region's emphasis on personalized medicine and biotechnology fuels growth.

In the Asia-Pacific region, the market is expanding rapidly due to increasing healthcare expenditures and a growing prevalence of chronic diseases. Countries like China and India are emerging as lucrative markets, owing to their large patient populations and rising demand for novel therapies. Latin America and the Middle East & Africa are also gaining traction. In Latin America, improvements in healthcare access and infrastructure drive market potential, while the Middle East & Africa benefit from increased investments in biotechnology and healthcare advancements.

Recent Developments:

The protein therapeutics market has experienced noteworthy developments over the past three months. Amgen announced a strategic collaboration with a leading biotech firm to enhance its protein engineering capabilities, aiming to accelerate drug discovery and development processes. This partnership is expected to significantly bolster Amgen\u2019s position in the protein therapeutics landscape.

In another significant move, Roche acquired a promising biotech company specializing in the development of novel protein-based therapies. This acquisition is set to enhance Roche\u2019s portfolio, providing access to innovative therapeutic candidates poised to address unmet medical needs across various therapeutic areas.

Regulatory advancements have also been prominent, with the FDA granting fast-track designation to a groundbreaking protein therapeutic developed by Biogen, aimed at treating a rare genetic disorder. This regulatory milestone underscores the potential of protein therapeutics in addressing complex medical conditions.

Meanwhile, Pfizer unveiled a cutting-edge protein therapeutic targeting a prevalent chronic disease, marking a significant addition to its existing product lineup. The launch is anticipated to drive substantial market growth, given the therapeutic\u2019s innovative mechanism of action.

Lastly, a joint venture between two pharmaceutical giants was announced, focusing on the development of next-generation protein therapeutics. This collaboration aims to leverage advanced technologies to create more effective and targeted therapies, highlighting the ongoing evolution and dynamism within the protein therapeutics market.

Key Trends and Drivers:

The Protein Therapeutics Market is experiencing robust growth, driven by advancements in biotechnology and a surge in chronic disease prevalence. Biopharmaceutical innovations are leading to the development of novel protein-based therapies, enhancing treatment efficacy and patient outcomes. These therapies are increasingly favored due to their specificity and reduced side effects compared to traditional pharmaceuticals.

A key trend is the expansion of monoclonal antibodies, which are gaining traction for their targeted action against cancer and autoimmune diseases. The market is also witnessing a rise in demand for biosimilars, driven by the expiration of patents and the need for cost-effective alternatives. This trend is further supported by regulatory frameworks that facilitate biosimilar approvals, expediting market entry.

Additionally, personalized medicine is emerging as a significant driver, with protein therapeutics playing a crucial role in tailoring treatments to individual genetic profiles. Investments in research and development are fostering innovation, while collaborations between biotech firms and academic institutions are accelerating discovery processes. The growing emphasis on precision medicine and targeted therapies is creating lucrative opportunities in the protein therapeutics landscape, promising substantial market expansion in the coming years.

Restraints and Challenges:

The protein therapeutics market is confronted with several significant restraints and challenges. One prominent challenge is the high cost of development and production, which increases the financial burden on manufacturers and consumers. Regulatory hurdles further complicate market entry, as stringent compliance requirements demand substantial time and resources. Intellectual property issues also present a barrier, with patent expirations leading to increased competition from biosimilars. Additionally, the complex nature of protein therapeutics necessitates advanced storage and distribution infrastructure, adding logistical difficulties and costs. Finally, limited patient access due to high prices and reimbursement issues restricts market expansion, particularly in developing regions. These factors collectively impede the growth and accessibility of the protein therapeutics market.

Key Companies:

Biocon, Sangamo Therapeutics, AbCellera Biologics, MacroGenics, Adaptimmune Therapeutics, BioNTech, CureVac, ImmunoGen, Kymab, Morphic Therapeutic, Pieris Pharmaceuticals, Sorrento Therapeutics, Argenx, Aptevo Therapeutics, Alector, Zymeworks, Allakos, Gritstone Oncology, Gossamer Bio, Harpoon Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Installation Type
  • 2.9 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Insulin
    • 4.1.3 Erythropoietin
    • 4.1.4 Interferons
    • 4.1.5 Colony Stimulating Factors
    • 4.1.6 Growth Hormones
    • 4.1.7 Coagulation Factors
    • 4.1.8 Enzyme Replacement
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Therapeutic Proteins
    • 4.2.2 Vaccines
    • 4.2.3 Peptide Hormones
    • 4.2.4 Blood Factors
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Recombinant DNA Technology
    • 4.3.2 Hybridoma Technology
    • 4.3.3 Transgenic Technology
    • 4.3.4 Cell Culture
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Cancer
    • 4.4.2 Metabolic Disorders
    • 4.4.3 Blood Disorders
    • 4.4.4 Autoimmune Diseases
    • 4.4.5 Infectious Diseases
    • 4.4.6 Neurological Disorders
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Research Institutes
    • 4.5.4 Biopharmaceutical Companies
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Injectable
    • 4.6.2 Oral
    • 4.6.3 Inhalable
    • 4.6.4 Topical
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Purification
    • 4.7.2 Formulation
    • 4.7.3 Lyophilization
  • 4.8 Market Size & Forecast by Installation Type (2020-2035)
    • 4.8.1 In-House
    • 4.8.2 Outsourced
  • 4.9 Market Size & Forecast by Equipment (2020-2035)
    • 4.9.1 Bioreactors
    • 4.9.2 Chromatography Systems
    • 4.9.3 Filtration Systems

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Form
      • 5.2.1.7 Process
      • 5.2.1.8 Installation Type
      • 5.2.1.9 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Form
      • 5.2.2.7 Process
      • 5.2.2.8 Installation Type
      • 5.2.2.9 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Form
      • 5.2.3.7 Process
      • 5.2.3.8 Installation Type
      • 5.2.3.9 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Form
      • 5.3.1.7 Process
      • 5.3.1.8 Installation Type
      • 5.3.1.9 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Form
      • 5.3.2.7 Process
      • 5.3.2.8 Installation Type
      • 5.3.2.9 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Form
      • 5.3.3.7 Process
      • 5.3.3.8 Installation Type
      • 5.3.3.9 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Form
      • 5.4.1.7 Process
      • 5.4.1.8 Installation Type
      • 5.4.1.9 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Form
      • 5.4.2.7 Process
      • 5.4.2.8 Installation Type
      • 5.4.2.9 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Form
      • 5.4.3.7 Process
      • 5.4.3.8 Installation Type
      • 5.4.3.9 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Form
      • 5.4.4.7 Process
      • 5.4.4.8 Installation Type
      • 5.4.4.9 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Form
      • 5.4.5.7 Process
      • 5.4.5.8 Installation Type
      • 5.4.5.9 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Form
      • 5.4.6.7 Process
      • 5.4.6.8 Installation Type
      • 5.4.6.9 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Form
      • 5.4.7.7 Process
      • 5.4.7.8 Installation Type
      • 5.4.7.9 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Form
      • 5.5.1.7 Process
      • 5.5.1.8 Installation Type
      • 5.5.1.9 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Form
      • 5.5.2.7 Process
      • 5.5.2.8 Installation Type
      • 5.5.2.9 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Form
      • 5.5.3.7 Process
      • 5.5.3.8 Installation Type
      • 5.5.3.9 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Form
      • 5.5.4.7 Process
      • 5.5.4.8 Installation Type
      • 5.5.4.9 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Form
      • 5.5.5.7 Process
      • 5.5.5.8 Installation Type
      • 5.5.5.9 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Form
      • 5.5.6.7 Process
      • 5.5.6.8 Installation Type
      • 5.5.6.9 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Form
      • 5.6.1.7 Process
      • 5.6.1.8 Installation Type
      • 5.6.1.9 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Form
      • 5.6.2.7 Process
      • 5.6.2.8 Installation Type
      • 5.6.2.9 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Form
      • 5.6.3.7 Process
      • 5.6.3.8 Installation Type
      • 5.6.3.9 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Form
      • 5.6.4.7 Process
      • 5.6.4.8 Installation Type
      • 5.6.4.9 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Form
      • 5.6.5.7 Process
      • 5.6.5.8 Installation Type
      • 5.6.5.9 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Biocon
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sangamo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 AbCellera Biologics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 MacroGenics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Adaptimmune Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 BioNTech
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 CureVac
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 ImmunoGen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Kymab
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Morphic Therapeutic
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Pieris Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Sorrento Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Argenx
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Aptevo Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Alector
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Zymeworks
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Allakos
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Gritstone Oncology
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Gossamer Bio
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Harpoon Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us